Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for…
Medical - Diagnostics & Research
US, Redwood City [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -122.27 | -30.15 | -13.57 | |
| Graham Fair Price | -49.92 | 3.45 | 6.90 | |
| PEG | 259.51 | 0.13 | -0.04 | |
| Price/Book | 78.67 | 36.09 | 20.20 | |
| Price/Cash Flow | -71.06 | -66.22 | -38.71 | |
| Prices/Earnings | -25.07 | -5.36 | -4.28 | |
| Price/Sales | -29.25 | 14.63 | 20.67 | |
| Price/FCF | -71.06 | -66.22 | -38.71 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -59.79 | 0.61 | 1.52 | |
| Operating Margin | 53.56 | -0.59 | -1.27 | |
| ROA | 35.57 | -0.07 | -0.10 | |
| ROE | -1.18 | -1.68 | -42.86 | |
| ROIC | -0.15 | -0.08 | 45.52 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | < 0.005 | -37.45 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.74 | 0.50 | -33.02 | |
| EPS QOQ | -1.16 | 0.41 | -65.21 | |
| FCF QOQ | -0.03 | 0.55 | 1570.42 | |
| Revenue QOQ | 0.08 | 0.09 | 3.09 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | -68.72 | 86.82 | 26.35 | |
| Days Sales Outstanding (DSO) | 51.53 | 45.17 | -12.35 | |
| Inventory Turnover | -1.31 | 1.04 | -20.85 | |
| Debt/Capitalization | 0.88 | 0.94 | 7.32 | |
| Quick Ratio | 6.11 | 5.52 | -9.65 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 1.34 | 0.56 | -58.10 | |
| Cash | 9.86 | 9.28 | -5.91 | |
| Capex | -0.03 | -0.06 | -65.60 | |
| Free Cash Flow | -0.70 | -0.31 | 56.24 | |
| Revenue | 1.31 | 1.38 | 5.81 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad